PRIOR AUTHORIZATION FORM

Mavenclad - Medicare



Unless otherwise indicated below, authorization quantities are limited to the manufacturer recommended dosage

P.O. Box 30196 Salt Lake City, UT 84130-0196 SELECTHEALTHADVANTAGE.ORG

Complete online at www.selecthealth.org/pa or fax back to: 801-442-0413 For questions or clarifications, call: 801-442-9988 or 855-442-9988	
Patient's Name:	Patient's Date of Birth:
Patient's ID:	Patient's Phone #:
Diagnosis Code(s):	
Requesting Provider Information	
Name:	Phone #:
NPI/DEA:	Fax #:
Address:	Supervising Physician (if requesting provider bills under a different provider) Name:
	NPI/DEA:
Servicing Provider Information (if different than requesting provider)	
Name of provider or facility:	Phone number:
NPI/DEA:	Address:
Drug Name and Strength:	Directions / SIG:
☐ Urgent Request (24 hours)	☐ Standard Request (72 hours)
Q1. Is this a reauthorization request?	
☐Yes	□ No
Q2. What is the patient's diagnosis? Relapsing-remitting multiple sclerosis (RRMS) Secondary progressive multiple sclerosis (SPMS) Other	
Q3. If other, please specify:	
Q4. Is the prescribing physician a neurologist?	
Yes	□ No

Q5. Has the patient been compliant on TWO of the following Gilenya Glatiramer acetate Plegridy None of the above	g preferred MS drugs? Please check all that apply:	
Q6. Will Mavenclad be used as monotherapy?		
☐ Yes	□ No	
Q7. Is the patient 18 years or older?		
☐Yes	□ No	
Q8. Has the patient had a recent CBC (within the previous 6 months)?		
☐Yes	□ No	
Q9. Has the patient had a liver function test within the previous 6 months?		
☐Yes	□ No	
Q10. For reauthorization, has the patient had a recent CBC (within the previous 6 months)?		
☐Yes	□ No	
Q11. Is the lymphocyte count at least 800 cells per microliter before initiating the second treatment course?		
☐ Yes	□No	
Q12. Additional comments:		
This form is intended for SelectHealth members only. All requests for preauthorization should be sent via fax to 1-801-442-0413. Missing, inaccurate, or incomplete information may cause a delay or denial of authorization.		
Prescriber Signature	Date	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document